DE69825075T2 - 5-(2-imidazolinylamino)-benzimidazol derivate, deren herstellung und deren verwendung als .alpha.-adrenoceptor agonisten mit verbesserter metabolischer stabilität - Google Patents

5-(2-imidazolinylamino)-benzimidazol derivate, deren herstellung und deren verwendung als .alpha.-adrenoceptor agonisten mit verbesserter metabolischer stabilität Download PDF

Info

Publication number
DE69825075T2
DE69825075T2 DE69825075T DE69825075T DE69825075T2 DE 69825075 T2 DE69825075 T2 DE 69825075T2 DE 69825075 T DE69825075 T DE 69825075T DE 69825075 T DE69825075 T DE 69825075T DE 69825075 T2 DE69825075 T2 DE 69825075T2
Authority
DE
Germany
Prior art keywords
imidazolinylamino
dimethyl
cyano
methylbenzimidazole
benzimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69825075T
Other languages
German (de)
English (en)
Other versions
DE69825075D1 (de
Inventor
Lee Thomas CUPPS
Lee Sophie BOGDAN
Nicholas Nikolaides
Ann Sheri GILBERT
Michael Gazda
Lee Roy DOBSON
Andrew Charles CRUZE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska Omaha
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of DE69825075D1 publication Critical patent/DE69825075D1/de
Application granted granted Critical
Publication of DE69825075T2 publication Critical patent/DE69825075T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69825075T 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazol derivate, deren herstellung und deren verwendung als .alpha.-adrenoceptor agonisten mit verbesserter metabolischer stabilität Expired - Lifetime DE69825075T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6676797P 1997-11-24 1997-11-24
US66767P 1997-11-24
US6670097P 1997-11-25 1997-11-25
US66700P 1997-11-25
PCT/US1998/024694 WO1999026942A1 (en) 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability

Publications (2)

Publication Number Publication Date
DE69825075D1 DE69825075D1 (de) 2004-08-19
DE69825075T2 true DE69825075T2 (de) 2005-08-25

Family

ID=26747058

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69825075T Expired - Lifetime DE69825075T2 (de) 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazol derivate, deren herstellung und deren verwendung als .alpha.-adrenoceptor agonisten mit verbesserter metabolischer stabilität

Country Status (23)

Country Link
US (1) US6486190B1 (enExample)
EP (1) EP1037887B1 (enExample)
JP (1) JP2001524478A (enExample)
KR (1) KR20010032435A (enExample)
CN (1) CN1284073A (enExample)
AT (1) ATE271048T1 (enExample)
BR (1) BR9815017A (enExample)
CA (1) CA2311344C (enExample)
CO (1) CO4970802A1 (enExample)
DE (1) DE69825075T2 (enExample)
ES (1) ES2223143T3 (enExample)
HU (1) HUP0101469A3 (enExample)
IL (1) IL136303A (enExample)
IN (1) IN190809B (enExample)
NO (1) NO20002655L (enExample)
NZ (1) NZ504707A (enExample)
PE (1) PE133699A1 (enExample)
PL (1) PL340711A1 (enExample)
RU (1) RU2193562C2 (enExample)
SK (1) SK7792000A3 (enExample)
TR (1) TR200002242T2 (enExample)
TW (1) TW505642B (enExample)
WO (1) WO1999026942A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081443A1 (en) 2001-04-09 2002-10-17 Chiron Corporation Novel guanidino compounds
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
RU2225401C1 (ru) * 2002-09-16 2004-03-10 Катаев Валерий Алексеевич 5(6)-нитро-1-(1,1-диоксотиетанил-3)-2-хлорбензимидазол, проявляющий биологическую активность
US20040167194A1 (en) * 2003-02-20 2004-08-26 Randall Jared Lynn Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form
US7268255B2 (en) * 2003-02-20 2007-09-11 Lonza Ag Process for the preparation of N-substituted formamides
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
ES2424644T3 (es) * 2004-05-25 2013-10-07 Galderma Pharma S.A. Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
RU2306137C1 (ru) * 2005-12-28 2007-09-20 Денис Вячеславович Лисицын Средство для профилактики и лечения гриппа
WO2013130577A2 (en) * 2012-02-27 2013-09-06 Eye Therapies, Llc Compositions and methods for the treatment of migraine
US20150133516A1 (en) * 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
KR20180105129A (ko) * 2015-11-30 2018-09-27 노부스 테라퓨틱스, 인크. 이과학적 예방 및 치료를 위한 조성물 및 방법
EA030197B1 (ru) * 2016-03-22 2018-07-31 Общество С Ограниченной Ответственностью "Рубикон" Таблетированная форма противовирусного лекарственного средства
JP7163014B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 感冒薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4036976A (en) 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
EP0025269B1 (en) 1979-08-23 1985-11-13 Beecham Group Plc Anti-diarrhoea veterinary composition
WO1982000824A1 (en) 1980-09-05 1982-03-18 Geissmann F 1h and 2h indazol derivatives and medicaments containing them
FR2638356A1 (fr) 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5180721A (en) 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
TW300219B (enExample) * 1991-09-14 1997-03-11 Hoechst Ag
US5478858A (en) 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
AU704972B2 (en) 1994-08-04 1999-05-13 H. Lundbeck A/S Novel benzimidazole derivatives
ID24081A (id) * 1997-04-15 2000-07-06 Procter & Gamble Senyawa-senyawa 5-(2-imidazolinilamino) benzimidazol yang berguna sebagai agonis-agonis alfa-2-adrenoseptor

Also Published As

Publication number Publication date
PL340711A1 (en) 2001-02-26
CN1284073A (zh) 2001-02-14
PE133699A1 (es) 2000-03-05
ES2223143T3 (es) 2005-02-16
CA2311344A1 (en) 1999-06-03
CO4970802A1 (es) 2000-11-07
KR20010032435A (ko) 2001-04-25
BR9815017A (pt) 2001-09-11
CA2311344C (en) 2006-02-07
IN190809B (enExample) 2003-08-23
HUP0101469A3 (en) 2003-01-28
IL136303A (en) 2004-02-08
HUP0101469A2 (hu) 2001-10-28
DE69825075D1 (de) 2004-08-19
TR200002242T2 (tr) 2000-11-21
EP1037887B1 (en) 2004-07-14
WO1999026942A8 (en) 2000-08-03
ATE271048T1 (de) 2004-07-15
US6486190B1 (en) 2002-11-26
IL136303A0 (en) 2001-05-20
EP1037887A1 (en) 2000-09-27
JP2001524478A (ja) 2001-12-04
NO20002655D0 (no) 2000-05-24
SK7792000A3 (en) 2001-01-18
NO20002655L (no) 2000-07-24
NZ504707A (en) 2002-11-26
WO1999026942A1 (en) 1999-06-03
RU2193562C2 (ru) 2002-11-27
TW505642B (en) 2002-10-11

Similar Documents

Publication Publication Date Title
CA2179008C (en) 5-(2-imidazolinylamino)benzimidazole derivatives, their preparation and their use as alpha-2 adrenoceptor agonists
DE69732244T2 (de) Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
DE69730516T2 (de) 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten
DE69425334T2 (de) 6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten
US6117871A (en) 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
DE69427591T2 (de) 7-(2-imidazolinylamino)quinolin-verbindungen als alpha-2 adrenorezeptor-agonisten
EP1037887B1 (en) 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
DE69424183T2 (de) 6-(2-imidazolinylamino)chinolin-verbindungen als alpha-2-adrenoceptor-antagonisten
DE69719068T2 (de) Guanidinylamino-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
US6436978B1 (en) Guanidinylamino heterocycle compounds useful as α-2 adrenoceptor agonists
CA2285610A1 (en) 5-(2-imidazolinylamino)benzimidazole compounds useful as alpha-2 adrenoceptor agonists
AU5433998A (en) 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonis ts
AU741774B2 (en) 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
MXPA00005120A (en) 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha. -adrenoceptor agonists with improved metabolic stability
CZ20001912A3 (cs) 5-(2-Imidazolinylamino)-benzimidazolové deriváty, jejich příprava a jejich použití jako alfa adrenoceptorové agonisty se zlepšenou metabolickou stálostí
CZ368099A3 (cs) Sloučenina obecného vzorce 5-(2- imidazolinylamino)benzimidazol, která je synergista alfa-2 adrenoceptoru a je použitelná pro léčení poruch modulovaných alfa-2 adrenoceptory

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

8364 No opposition during term of opposition